The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to ...

The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

This is the same amount suggested for a balanced non-diabetic diet. About 45% to 65% of your caloric intake should come from carbohydrates and the rest should come from fat. Some health experts ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections compared to Eylea. Read more here.

see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy . Full details of the evidence and the committee's discussion are in evidence review E: ...